Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 25;27(4):80.
doi: 10.1208/s12248-025-01073-2.

TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery

Bishal Misra  1 , Krystal A Hughes  1 , William H Pentz  1   2 , Morgan Surface  1 , Werner J Geldenhuys  1 , Sharan Bobbala  3
Affiliations

TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery

Bishal Misra et al. AAPS J. .

Abstract

Ionizable lipid nanoparticles (LNPs) are clinically relevant non-viral vectors that allow intracellular delivery of mRNA vaccines to immune cells. To fight against notorious pathogens and cancer, mRNA vaccines necessitate the addition of an adjuvant to induce strong and durable cell-mediated immune responses. Adjuvants that stimulate Toll-like receptor 7 (TLR7) induce the secretion of type I interferons and proinflammatory cytokines, vital for generating strong immune responses. However, the intracellular delivery of TLR7 adjuvants to precisely stimulate the endosomal TLR7 receptor remains a huge challenge. This issue can be addressed by exploiting ionizable LNP platforms, which can encapsulate and carry mRNA vaccines and small molecule hydrophobic adjuvants to immune cells. CL347 is a potent lipid-based adjuvant that selectively stimulates the TLR7 receptor. In this study, we developed ionizable LNPs incorporating SM102 and CL347 adjuvant as the ionizable lipid and TLR7 adjuvant, respectively. CL347-SM102 LNPs exhibited particle sizes of less than 150 nm with spherical morphology and mRNA encapsulation efficiency of greater than 95%. In vivo studies showed a two-fold increase in IFN-γ producing CD4 and CD8 T cells in the lymphoid organs of the mice immunized with adjuvanted LNPs compared to the non-adjuvanted LNPs. Human PBMCs treated with adjuvanted LNPs exhibited significantly higher CD40 expression and pro-inflammatory cytokine (IL-6 and IFN-γ) secretion than non-adjuvanted LNPs. Together, these results suggest the potential of ionizable LNPs as a platform for concurrent delivery of mRNA and adjuvants for prophylactic and therapeutic vaccine applications.

Keywords: adjuvants; ionizable Lipids; lipid nanoparticles; mRNA vaccine; toll-like receptors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: All authors state that there are no conflicts to declare.

References

    1. Han X, Zhang H, Butowska K, Swingle KL, Alameh M-G, Weissman D, et al. An ionizable lipid toolbox for RNA delivery. Nat Commun. 2021;12(1). https://doi.org/10.1038/s41467-021-27493-0 .
    1. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172–6. https://doi.org/10.1038/nbt.1602 . - DOI
    1. Tang X, Zhang Y, Han X. Ionizable lipid nanoparticles for mRNA delivery. Adv NanoBiomed Res. 2023;3(8):2300006. https://doi.org/10.1002/anbr.202300006 . - DOI
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16. https://doi.org/10.1056/nejmoa2035389 . - DOI
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/nejmoa2034577 . - DOI

Publication types

MeSH terms

LinkOut - more resources